Marshall Wace’s Carisma Therapeutics CARM Stock Holding History

Marshall Wace’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,997	Closed	-$308K	–	3397
2021 Q4	$308K	Buy	18,997 +15,076	+384%	+$303K	﹤0.01%	3025
2021 Q3	$62K	Buy	+3,921	New	+$188K	﹤0.01%	2924

Other funds holding CARM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace's CARM Position: Q1 2022 in Review

Marshall Wace sold out of Carisma Therapeutics (CARM) in Q1 2022, closing a stake of 18,997 shares — an estimated $308K sold.

Marshall Wace first reported a position in CARM in Q3 2021 and held it in 2 quarters. The position peaked at $308K in Q4 2021. 84 funds tracked by Wall St. Rank hold CARM as of Q1 2022.

Marshall Wace reported no remaining Carisma Therapeutics position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 18,997 Carisma Therapeutics shares in Q1 2022, an estimated $308K.
Marshall Wace first reported a position in Carisma Therapeutics in Q3 2021 and held it in 2 quarters.
Marshall Wace's Carisma Therapeutics position peaked at $308K in Q4 2021.
84 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.